



10 May 2023

Sean Maloney
Australian Securities Exchange
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

By email: Sean.Maloney@asx.com.au

Dear Sir

Creso Pharma Limited (ASX: CPH) – Response to Price Query

We refer to your letter dated 9 May 2023 in which you queried the recent trading of Creso Pharma Limited (the “Company” or “Creso”) shares.

In response to your questions outlined in the letter, we provide the following information:

1. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in the Company’s securities.
2. Not applicable.
3. Within the last three trading days, the Company announced:
 - a) promising preliminary results from a phase two clinical trials being undertaken by wholly owned subsidiary, Halucenex Life Sciences Inc, to test the efficacy of psilocybin on treatment-resistant post-traumatic stress disorder; and
 - b) that the Scheme of Arrangement to acquire 100% of the issued capital of Health House International Limited (“HHI”) became effective, with the transaction set to complete on 16 May 2023. The transaction provides several significant strategic benefits to Creso, particularly in relation to the strong cash receipts and revenues of HHI which Creso will be able to recognise on consolidation.
4. The Company confirms it is in compliance with the Listing Rules, in particular Listing Rule 3.1.
5. The Company confirms its responses to the above questions have been authorised and approved by an officer with delegated authority by the Board to respond to ASX on disclosure matters.

Yours faithfully,

Erlyn Dawson
Joint Company Secretary



9 May 2023

Reference: 74139

Ms Erlyn Dale
Company Secretary
Creso Pharma Limited

By email:

Dear Ms Dale

Creso Pharma Limited ('CPH'): Price - Query

ASX refers to the following:

- A. The change in the price of CPH's securities from a low of \$0.012 on Monday, 8 May 2023 to an intraday high of \$0.018 today, 9 May 2023.
- B. The significant increase in the volume of CPH's securities traded from Monday, 8 May 2023 to today, 9 May 2023.

Request for information

In light of this, ASX asks CPH to respond separately to each of the following questions and requests for information:

1. Is CPH aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
 - (a) Is CPH relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in CPH's securities would suggest to ASX that such information may have ceased to be confidential and therefore CPH may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that CPH may have for the recent trading in its securities?
4. Please confirm that CPH is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that CPH's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of CPH with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **3:00 PM AWST Tuesday, 9 May 2023**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, CPH's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require CPH to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsCompliancePerth@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in CPH's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in CPH's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to CPH's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that CPH's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours sincerely

Sean Maloney
Senior Adviser, Listings Compliance